Esperion Therapeutis.Inc. buy Needham & Company LLC
Summary
This prediction is currently active. The prediction for Esperion Therapeutis.Inc. disappoints with a performance of -26.19%. This prediction currently runs until 25.03.25. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | -2.985% | -2.985% |
iShares Core DAX® | 2.594% | -1.861% |
iShares Nasdaq 100 | 3.553% | -2.064% |
iShares Nikkei 225® | 0.687% | -8.704% |
iShares S&P 500 | 2.209% | -1.988% |
Comments by Needham___Company_LL for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by Needham___Company_LL for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
10.04.24
10.04.25
26.04.24
Esperion Therapeutis.Inc.
27.02.24
27.02.25
26.04.24
Esperion Therapeutis.Inc.
07.11.23
07.11.24
26.04.24
Esperion Therapeutis.Inc.
02.10.23
02.10.24
26.04.24
Esperion Therapeutis.Inc.
02.08.23
02.08.24
26.04.24
Esperion Therapeutis.Inc.
29.03.23
29.03.24
30.03.24
Esperion Therapeutis.Inc.
06.03.23
06.03.24
07.03.24